Bank of America
CMPX icon

Bank of America’s Compass Therapeutics CMPX Stock Holding History

Bank of America’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.58M Buy
865,613
+599,179
+225% +$3.46M ﹤0.01% 3536
2025
Q4 		$1.43M Buy
266,434
+192,633
+261% +$890K ﹤0.01% 4303
2025
Q3 		$258K Buy
73,801
+41,252
+127% +$130K ﹤0.01% 6156
2025
Q2 		$84.6K Sell
32,549
-350,954
-92% -$724K ﹤0.01% 6601
2025
Q1 		$729K Buy
383,503
+270,483
+239% +$719K ﹤0.01% 5444
2024
Q4 		$164K Buy
113,020
+30,303
+37% +$50.3K ﹤0.01% 6200
2024
Q3 		$152K Buy
82,717
+17,993
+28% +$22.4K ﹤0.01% 6148
2024
Q2 		$64.7K Buy
64,724
+19,310
+43% +$28.2K ﹤0.01% 6434
2024
Q1 		$89.9K Sell
45,414
-46,082
-50% -$79.6K ﹤0.01% 6294
2023
Q4 		$143K Sell
91,496
-22,662
-20% -$39.2K ﹤0.01% 6236
2023
Q3 		$225K Buy
114,158
+38,844
+52% +$96K ﹤0.01% 5846
2023
Q2 		$239K Sell
75,314
-18,666
-20% -$58.6K ﹤0.01% 5724
2023
Q1 		$307K Buy
93,980
+93,898
+114,510% +$369K ﹤0.01% 5685
2022
Q4 		$412 Buy
+82
New +$327 ﹤0.01% 7459
2022
Q2 		– Sell
-6
Closed – – 8054
2022
Q1 		$0 Buy
+6
New +$12 ﹤0.01% 8307

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's CMPX Position: Q1 2026 in Review

Bank of America increased its Compass Therapeutics (CMPX) stake by 225% in Q1 2026, buying an estimated $3.46M and bringing the position to 865,613 shares worth $4.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3536.

Bank of America first reported a position in CMPX in Q1 2022 and has held it in 15 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Bank of America held 865,613 shares of Compass Therapeutics worth $4.58M as of Q1 2026.
  • Bank of America bought 599,179 Compass Therapeutics shares in Q1 2026, an estimated $3.46M.
  • Compass Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3536 holding.
  • Bank of America first reported a position in Compass Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.